Company Analysis Akoya Biosciences, Inc.
1. Summary
Advantages
- Price (3.2 $) is less than fair price (4.24 $)
- The stock's return over the last year (-16.01%) is higher than the sector average (-29.77%).
Disadvantages
- Dividends (0%) are below the sector average (0.5491%).
- Current debt level 43.63% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-117.77%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Akoya Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.2% | -16.4% | -1.8% |
| 90 days | 23.1% | -46.1% | 6.3% |
| 1 year | -16% | -29.8% | 34.5% |
AKYA vs Sector: Akoya Biosciences, Inc. has outperformed the "Healthcare" sector by 13.76% over the past year.
AKYA vs Market: Akoya Biosciences, Inc. has significantly underperformed the market by -50.54% over the past year.
Stable price: AKYA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AKYA with weekly volatility of -0.3079% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3.2 $) is lower than the fair price (4.24 $).
Price significantly below the fair price: The current price (3.2 $) is 32.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.19) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (4.19) is higher than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.33) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (2.33) is lower than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.83) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.83) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 65.86% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (65.86%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-117.77%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-117.77%) is lower than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (-35.11%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-35.11%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 11.06.2024 | McKelligon Brian President and CEO |
Sale | 2.08 | 15 600 | 7 500 |
| 11.06.2024 | McKelligon Brian President and CEO |
Purchase | 0.3 | 2 250 | 7 500 |
| 07.09.2023 | Pla Frederic Chief Operating Officer |
Purchase | 4.6 | 92 000 | 20 000 |
| 22.12.2022 | DRISCOLL JOSEPH Chief Financial Officer |
Purchase | 0.44 | 110 000 | 250 000 |
| 02.12.2022 | Nolan Garry Ph.D. Director |
Sale | 13.25 | 14 575 | 1 100 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
